🔗 Share this article

Given that the US proceeds with sweeping adjustments to its vaccination guidelines, a particular individual has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccines throughout the pandemic and has focused upon alleged fatalities after Covid vaccination in her short time at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Immunization Program

Agency leaders had intended to announce major revisions to the pediatric vaccine schedule earlier this month, aligning the US with the Danish immunization schedule, according to reports – a significant shift that would place the US out of step with many the international standard with no evidence for improved outcomes. The announcement has been delayed until the next year.

Rather than the top vaccines chief, Dr. Høeg is scheduled to address the audience at the event. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this calendar year.

A Shift at the Agency

The acting appointment might represent a tighter collaboration between the drug and vaccine branches as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain pediatric vaccine recommendations in the US so as to align more similar to Denmark's approach, a nation with universal health coverage and a population roughly the size of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on vaccines – usually the responsibility of Dr. Prasad, director of the FDA’s CBER – rather than drug regulation.

Concerns Over Background

Høeg has no apparent track record in drug development, approval processes or administrative roles, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and CBER since March.

“It seems she lacks to have the requisite experience” for leading the CDER, said Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in running a large organization. She is not an expert in pharmaceutical oversight.”

Past heads of CBER would “understand laws and regulations and the underlying principles of drug development”, said a former acting FDA commissioner. “Frankly, she has not acquired the sort of resume that former directors who ran CBER have had.”

The drug center has an vast range of responsibilities at the FDA, she stated.

“Many people just focuses on the novel medication approvals, but the generic drug division clears thousands of generic medications. There’s a biosimilars program, over-the-counter program and so forth, and all of those must be supervised,” she noted. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

There is also, a major management component to the position, which supervises in excess of 5,000 personnel. “It is a massive administrative position, if you do it right,” Woodcock said.

Agency Reaction and Disputed Programs

When asked about concerns about Dr. Høeg's fitness for the role and whether this assignment represents greater collaboration among agency officials on immunizations, a press secretary said that the “questions stem from incorrect presumptions”.

“Her resume is consistent with the functions of her job,” the representative explained, noting the time Høeg spent guiding the agency head on “medication safety and approval science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a disputed rapid therapy clearance system that allegedly worried her predecessors. “By what process are these medications being chosen for this expedited pathway? Who takes the choices?” Dr. Howard asked. “There is a lot of lack of transparency happening at the FDA right now.”

In general, he remarked, “the agency seems to be moving towards more relaxed rules of most medications, except for vaccines.”

Documented Past Work on Vaccines

Regarding vaccines, Høeg has a clearer, if problematic, history, Howard have noted. She authored a analysis using unverified public submissions to determine the frequency of myocarditis after COVID-19 vaccination. She counseled the Florida surgeon general Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Part of her “policy goals” for the new administration encompassed changing guidelines for new vaccines and halting “optional” immunizations, she remarked after the election on a online show. At the FDA, Dr. Høeg has allegedly proposed barring young men from getting Covid vaccines.

“She’s an all-around true believer who commences with her preconceived notions and reverse-engineers to retrofit the evidence in a very disingenuous, fraudulent manner,” Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined fellow dissenters, {like|